다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc (ARCT) 뉴스

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ARCT

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/03/07	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/02/25	06:01	Business Wire	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/02/14	22:30	PR Newswire (US)	European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/02/14	22:00	Business Wire	European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/02/04	22:30	Business Wire	Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/01/31	17:00	Business Wire	Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/01/31	06:01	Business Wire	Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/01/10	22:00	Business Wire	Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2025/01/07	06:01	Business Wire	Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/12/19	06:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/12/17	06:01	Business Wire	Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/11/27	06:01	Business Wire	Arcturus Therapeutics to Attend Upcoming Investor Conferences	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/11/19	10:00	Business Wire	Arcturus Therapeutics to Present at Jefferies London Healthcare Conference	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/11/14	15:00	Business Wire	Meiji Seika Pharma Announces Investment in ARCALIS, Inc.	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/11/12	06:01	Business Wire	Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/11/08	06:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/11/08	06:01	Business Wire	Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/11/01	05:01	Business Wire	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/09/30	21:00	PR Newswire (US)	Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/09/30	21:00	Business Wire	Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/09/13	21:15	PR Newswire (US)	Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/09/13	21:00	Business Wire	Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/09/03	21:30	Business Wire	Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/08/28	06:00	Business Wire	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/08/13	20:54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/08/06	05:50	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/08/06	05:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/08/06	05:01	Business Wire	Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/08/02	05:01	Business Wire	Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc
2024/07/19	08:30	Business Wire	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024	NASDAQ:ARCT	Arcturus Therapeutics Holdings Inc

검색 관련기사 보기:NASDAQ:ARCT

1 2 3 4 5 6 7 8 9 10 다음 >>

US Dollar vs Euro

Invesco QQQ Trust Series 1

JP Morgan Chase

US Dollar vs Yen

Health Care Select Sector

Deutsche Telekom (QX)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관